Analysis of fibrinolytic proteins in relation to DNA ploidy in prostate cancer

International Journal of Cancer

Volumn 78, Issue 3, 1998, Pages 320-325

  Plas, Eugen ^a,c   Carroll, Veronica A ^b   Jilch, Ruth ^c   Mihaly, Judith ^a,b   Vesely, Michael ^c   Ulrich, Walter ^c   Pfluger, Heinz ^a   Binder, Bernd R ^b  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c GENERAL HOSPITAL LINZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC FACTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PLOIDY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; TISSUE LEVEL;

AGED; DNA; DNA, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLOIDIES; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, CELL SURFACE; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 0032578720     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19981029)78:3<320::AID-IJC11>3.0.CO;2-A     Document Type: Article

References (28)

1. ACHBAROU, A., KAISER, S., TREMBLAY, G., STE-MARIE, L.G., BRODT, P., GOLTZMANN, D. and RABBANI, S.A., Urokinase over-production results in increased skeletal metastasis by prostate-cancer cells in vivo. Cancer Res., 54, 2372-2377 (1994).
2. BHATTI, R.A., GADAROWSKI, J.J. and RAY, P.S., Metastatic behavior of prostatic tumor as influenced by the hematopoetic and hematogenous factors. Tumor Biol, 18, 1-5 (1997).
3. CAMIOLO, S.M., MARKUS, G., ENGLANDER, L.S., SUITA, M.R., HOBIKA, G.H. and KOGHA, S.S., Plasminogen-activator content and secretion in explants of neoplastic and benign human prostate. Cancer Res., 4, 311-318 (1984).
4. CHO, J.Y., CHUNG, H.C., NOH. S.H., ROH, J.K., MIN, J.S. and KIM, B.S., High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. Cancer, 79, 878-883 (1997).
5. CHODAK, G.W., THISTED, R.A., GERBER, G.S., JOHANSSON, J.E., ADOLFSSON, J., JONES, G.W., CISHOLM, G.D., MOSKOVITZ, B., LIVNE, P.M. and WARNER, J., Results of conservative management of clinically localized prostate cancer. New Engl. J. Med., 330, 242-248 (1994).
6. CROWLEY, C.W., COHEN, R.L., LUCAS, B.K., Liu, G. and SHUMAN, M.A., Prevention of metastasis by inhibition of the urokinase receptor. Proc. nat. Acad. Sci. (Wash.), 90, 5021-5025 (1993).
7. DANØ, K., ANDREASEN, A., GRONDAHL-HANSEN, J., NIELSEN, L.S. and SKRIVER, L., Plasminogen activators, tissue degradation and cancer. Advanc. Cancer Res., 44, 139-266 (1985).
8. DEITCH, A.D. and DEVEREWHITE, R.W., Flow cytometry as a predictive modality in prostate cancer. Hum. Pathol, 23, 352-359 (1992).
9. FERNÖ, M., BENDAHL, P.O., BORG, A., BRUNDELL. J., HIRSCHBERG, L., OLSSON, H. and KILLANDER, D., Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid-receptor cytosols with a luminometric immuno-assay. Europ. J. Cancer, 32A, 793-801 (1996).
10. FRANKFURT, O.S., CHIN, J.L., ENGLANDER, L.S., GRECO, W.R., PONTES, J.E. and RUSTUM, Y.M., Relationship between DNA ploidy, glandular differentiation and tumor spread in human prostate cancer. Cancer Res., 45, 1418-1423 (1985).
11. GAYLIS, F.D., KERR, H.N., WILSON, M.J., KWAAN, H.C., SINHA, A.A. and KOZLOWSKI, J.M., Plasminogen activator in human prostate-cancer cell lines and tumors: correlation with the aggressive phenotype. J. Urol., 142, 193-198 (1989).
12. GRIGNON, D.J. and HAMMOND, E.H., College of American Pathologist Conference XXVI on clinical relevance of prognostic markers in solid tumors: report of the prostate-cancer working group. Arch. Pathol. Lab. Med., 119, 1122-1126 (1995).
13. HASUI, Y., MARUTSUKA, K., ASADA, Y. and OSADA, Y., Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer. Urology, 47, 34-37 (1996).
14. HASUI, Y., SUZUMIYA, J., MARUTSUKA, K., SUMIYOSHI, A., HASHIDA, S. and ISHIKAWA, E., Comparative study of plasminogen activators in cancer and normal mucosa of human urinary bladder. Cancer Res., 49, 1067-1070 (1989).
15. HERMANN, C.J., Cytometric DNA analysis in the management of cancer. Cancer, 69, 1553-1556 (1992).
16. HIENERT, G., KIRCHHEIMER, J.C., PFLÜGER, H. and BINDER. B.R., Urokinase-type plasminogen activator as a marker for the formation of distant metastasis in prostatic carcinomas. J. Urol., 140, 1466-1469 (1988).
17. HOOSEIN, N.M., BOYD, D.D., HOLLAS, W.J., MAZAR, A., HENKIN, J. and CHUNG, L.W.K., Involvement of urokinase and its receptor in the invasiveness of human prostatic-cancer cell lines. Cancer Comm., 3, 255-264 (1991).
18. JANKUN, J., KECK, R.W., SKRZYPCZAK-JANKUN, E. and SWIERCZ, R., Inhibitor of urokinase reduces size of prostate cancer xenografts in severe combined immunodeficient mice. Cancer Res., 57, 559-563 (1997).
19. KERR, H.N., GAYLIS, F.D., KOZLOWSKI, J.M., KWAAN, H.C., BAUER, K.D., SINHA, A.A. and WILSON, M.J., Heterogeneity in plasminogen-activator (PA) levels in human prostate-cancer cell lines: increased PA activity correlates with biologically aggressive behaviour. Prostate, 118, 201-214 (1991).
20. KIRCHHEIMER, J.C., KOLLER, A. and BINDER, B.R., Isolation and characterization of plasminogen activators from hyperplastic and malignant prostate tissue. Biochem. biophys. Acta, 797, 256-265 (1984).
21. KORETZ, K., MOLLER, P. and SCHWARTZ-ALBIEZ, R., Plasminogen activators and plasminogen-activator inhibitor in human colorectal-carcinoma tissues are not expressed by the tumor cells. Europ. J. Cancer, 29A, 1184-1189 (1993).
22. LAHIO, M. and KESKI-OJA, J., Growth factors in the regulation of pericellular proteolysis: a review. Cancer Res., 49, 2533-2553 (1989).
23. RABBANI, S.A., HARAKIDAS, P., DAVIDSON, D.J., HENKIN, J. and MAZAR, A.P., Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase plasminogen activator. Int. J. Cancer, 63, 840-845 (1995).
24. SCHRÖDER. F. and TRIBUKAIT, B., Clinical utility of cellular DNA measurement in prostate carcinoma. Scand. J. Urol. Nephrol., Suppl., 162, 51-64 (1994).
25. SHANKEY, T.V., KALLIONIEMI, O.P., KOSLOSKI, J.M., LIEBER. M.L., MAYALL, B.H., MILLER, G. and SMITH, G.J., Consensus review of the clinical utility of DNA-content cytometry in prostate cancer. Cytometry, 14, 497-500 (1993).
26. TAKAI, S., YAMAMURA, M., TANAKA, K., KAWANISHI, H., TSUJI, M., NAKANE, Y., HIOKI, K. and YAMAMOTO, M., Plasminogen activators in human gastric cancers: correlation with DNA ploidy and Immunohistochemical staining. Int. J. Cancer, 48, 20-27 (1991).
27. TAN, K., POWE, D.G., GRAY, T., TURNER, D.R. and HEWITT, R.E., Regional variations of urokinase-type plasminogen activator in human colorectal cancer: a quantitative study by image analysis. Int. J. Cancer, 60, 308-314 (1995).
28. TRIBUKAIT, B., Flow cytometry in assessing the clinical aggressiveness in genito-urinary neoplasms. Wld J. Urol., 5, 108-122 (1987).